AGC
MTACU

Angelo Gordon & Co’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

Angelo Gordon & Co’s Portfolio MTACU Stock Details MTACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-300,000
Closed -$3.15M – 191
2020
Q4 		$3.15M Buy
+300,000
New +$3.13M 0.28% 43

Other funds holding MTACU

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Angelo Gordon & Co's MTACU Position: Q1 2021 in Review

Angelo Gordon & Co sold out of MedTech Acquisition Corporation Unit (MTACU) in Q1 2021, closing a stake of 300,000 shares — an estimated $3.15M sold.

Angelo Gordon & Co first reported a position in MTACU in Q4 2020 and held it in 1 quarter. The position peaked at $3.15M in Q4 2020. 31 funds tracked by Wall St. Rank hold MTACU as of Q1 2021.

  • Angelo Gordon & Co reported no remaining MedTech Acquisition Corporation Unit position as of Q1 2021 after selling out during the quarter.
  • Angelo Gordon & Co sold 300,000 MedTech Acquisition Corporation Unit shares in Q1 2021, an estimated $3.15M.
  • Angelo Gordon & Co first reported a position in MedTech Acquisition Corporation Unit in Q4 2020 and held it in 1 quarter.
  • Angelo Gordon & Co's MedTech Acquisition Corporation Unit position peaked at $3.15M in Q4 2020.
  • 31 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q1 2021.

Based on Angelo Gordon & Co's 13F filing for Q1 2021, filed 17 May 2021.